What Does LivaNova (LIVN) Do? — Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters
LivaNova (LIVN) is a global medical-device company providing cardiopulmonary and neuromodulation devices. Earnings and share performance are driven by heart-surgery demand, neuromodulation device growth, and new product launches, while its position in specialty fields is a defining feature — drawing strong interest in its outlook and related stocks.
🏢 What kind of company is LivaNova?
LivaNova (LIVN) is a global medical-device company providing cardiopulmonary and neuromodulation devices. Headquartered in the UK, it supplies cardiopulmonary equipment such as heart-lung machines and oxygenators for cardiac surgery, along with neuromodulation devices such as vagus nerve stimulation for treating epilepsy and depression.
The company is built on two main pillars: a cardiopulmonary segment supplying heart-lung machines, oxygenators, and other cardiopulmonary equipment for cardiac surgery, and a neuromodulation segment supplying vagus nerve stimulation devices for treating epilepsy and treatment-resistant depression. It is a specialty medical-device company whose strengths lie in its specialized positioning in cardiopulmonary and neuromodulation and in recurring consumables and procedure demand.
How does LivaNova make money?| Business Segment | Revenue Share | Description |
|---|---|---|
| Cardiopulmonary | Core | Heart-lung machines and oxygenators |
| Neuromodulation | Key growth pillar | Vagus nerve stimulation devices |
| Consumables & Services | Diversification pillar | Revenue from consumables and procedure-related services |
Recent revenue is generated mainly from cardiopulmonary equipment and neuromodulation devices, with cardiac surgery demand, the expansion of neuromodulation therapy, and new product launches determining earnings. A stable market position in cardiopulmonary and recurring consumables revenue provide a steady base, while expanding indications for vagus nerve stimulation and new products add growth drivers. The structure is one in which surgical volumes, neuromodulation adoption, and new products shape the earnings trajectory.
📐 LivaNova market cap and company scale
Market capitalization stands at $4.4B, with an employee headcount of 3,300명.
As a specialty medical-device company in cardiopulmonary and neuromodulation, LivaNova occupies a position comparable to large-cap medical-device players such as BSX (Boston Scientific), MDT (Medtronic), and EW (Edwards Lifesciences). Its strengths lie in its specialized positioning in cardiopulmonary and neuromodulation and in recurring consumables and procedure demand, with earnings tied to surgical demand and neuromodulation growth.
📈 LivaNova outlook and share-price trends
Recovery in cardiac surgery demand, the expansion of indications for vagus nerve stimulation, new indications such as treatment-resistant depression, and new product launches are the key medium- to long-term growth drivers. A stable market position in cardiopulmonary and recurring consumables revenue provide a steady base, while neuromodulation growth lifts profitability. In the near term, however, intensifying medical-device competition, delays in new product and indication approvals, a slowdown in hospital capital spending, and FX volatility can act as potential sources of volatility.
- Recovery in cardiac surgery demand
- Expansion of indications for vagus nerve stimulation
- New product launches
⚔️ LivaNova's core strengths and risks
Specialized positioning in cardiopulmonary and neuromodulation, recurring consumables revenue, and the expansion of neuromodulation indications are strengths, while intensifying medical-device competition, delays in new product approvals, and FX volatility are the key risks.
Core Strengths
Core Risks
🔄 LivaNova's competitors and related (beneficiary) stocks
Comparable names in the medical-device space include BSX (Boston Scientific), MDT (Medtronic), and EW (Edwards Lifesciences). Related names grouped under the medical-device theme include ABT (Abbott) in diagnostics and devices, and ZBH (Zimmer Biomet) in orthopedic devices, which share exposure to medical-device demand.
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| BSX | Boston Scientific Corp | $46.73 | +1.6% | $69.5B | 19.0 | 2.7 | 14.83% | - |
| MDT | Medtronic Plc | $85.39 | -0.4% | $109.3B | 22.9 | 2.2 | 9.85% | 3.39% |
| EW | Edwards Lifesciences Corp | $86.07 | -1.0% | $49.6B | 51.1 | 4.8 | 10.52% | - |
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| ABT | Abbott Laboratories | $105.70 | +0.1% | $182.9B | 34.2 | 3.6 | 10.63% | 2.36% |
 ZBH | Zimmer Biomet Holdings Inc | $93.93 | -1.1% | $18.2B | 24.4 | 1.4 | 6.07% | 1.11% |
✅ LivaNova investor checkpoints
Key checkpoints when investing in LivaNova. Cardiac surgery demand, neuromodulation device growth, indication expansion, new product launches, and FX are the core short- and medium-term variables.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| 🫀 Cardiopulmonary Demand | Cardiac surgery and cardiopulmonary equipment demand | Steady trend |
| 🧠 Neuromodulation | Vagus nerve stimulation growth | Indication expansion |
| 🆕 New Products | New product and indication approvals | Under monitoring |
| 💱 FX | Global FX volatility | Volatility factor |
Intensifying competition in the medical-device field is the key risk. Delays in new product and indication approvals, a slowdown in hospital capital spending, and FX volatility in the global business can also act as swing factors for earnings.
LivaNova is a specialty medical-device company spanning cardiopulmonary and neuromodulation, with strengths in its specialized positioning, recurring consumables revenue, and the expansion of neuromodulation indications. Given the intensifying competition and sensitivity to new product approvals, however, a phased buying approach and a long-term perspective are recommended.
이 글은 2026년 6월 7일 기준 정보입니다.